Literature DB >> 8557112

The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a.

T Nishiki1, Y Tokuyama, Y Kamata, Y Nemoto, A Yoshida, K Sato, M Sekiguchi, M Takahashi, S Kozaki.   

Abstract

125I-labeled botulinum type B neurotoxin was shown to bind specifically to recombinant rat synaptotagmins I and II. Binding required reconstitution of the recombinant proteins with gangliosides GT1b/GD1a. Scatchard plot analyses revealed a single class of binding site with dissociation constants of 0.23 and 2.3 nM for synaptotagmin II and synaptotagmin I, respectively, values very similar to those of the high- (0.4 nM) and low-affinity (4.1 nM) binding sites in synaptosomes. The high-affinity binding of neurotoxin to synaptosomes was specifically inhibited by a monoclonal antibody recognizing with the amino-terminal region of synaptotagmin II. These results suggest that this region of synaptotagmin II participates in the formation of the high-affinity toxin binding site by associating with specific gangliosides.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8557112     DOI: 10.1016/0014-5793(95)01471-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  54 in total

1.  Unique biological activity of botulinum D/C mosaic neurotoxin in murine species.

Authors:  Keiji Nakamura; Tomoko Kohda; Yuto Shibata; Kentaro Tsukamoto; Hideyuki Arimitsu; Mitsunori Hayashi; Masafumi Mukamoto; Nobuyuki Sasakawa; Shunji Kozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

2.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

Review 3.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 4.  Botulinum neurotoxin - from laboratory to bedside.

Authors:  K A Foster; H Bigalke; K R Aoki
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

5.  Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.

Authors:  Alessandra Flores; Jorge Ramirez-Franco; Richard Desplantes; Kévin Debreux; Géraldine Ferracci; Florian Wernert; Marie-Pierre Blanchard; Yves Maulet; Fahamoe Youssouf; Marion Sangiardi; Cécile Iborra; Michel Robert Popoff; Michael Seagar; Jacques Fantini; Christian Lévêque; Oussama El Far
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-20       Impact factor: 11.205

6.  Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction.

Authors:  Cesare Colasante; Ornella Rossetto; Laura Morbiato; Marco Pirazzini; Jordi Molgó; Cesare Montecucco
Journal:  Mol Neurobiol       Date:  2013-03-08       Impact factor: 5.590

7.  Roles of the Mevalonate Pathway and Cholesterol Trafficking in Pulmonary Host Defense.

Authors:  Kristin A Gabor; Michael B Fessler
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

8.  Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek; Lance E Steward; K Roger Aoki
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

9.  Glycosylated SV2A and SV2B mediate the entry of botulinum neurotoxin E into neurons.

Authors:  Min Dong; Huisheng Liu; William H Tepp; Eric A Johnson; Roger Janz; Edwin R Chapman
Journal:  Mol Biol Cell       Date:  2008-09-24       Impact factor: 4.138

Review 10.  Interaction of botulinum toxin with the epithelial barrier.

Authors:  Yukako Fujinaga
Journal:  J Biomed Biotechnol       Date:  2010-02-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.